Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

OfficialStocktwitsUser Jan. 28 at 2:52 AM

$KALA RSI: 40.52, MACD: -0.0501 Vol: 0.03, MA20: 0.61, MA50: 0.69 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ALOSETE Jan. 27 at 9:38 PM

$KALA Nice close. In lazar we trust.🤑

0 · Reply

EF5Stocks Jan. 27 at 6:56 PM

$KALA Very low volume selling.....meeting coming up; happens to coincide with potential "W" double bottom pattern on 6mo. - 1yr. chart. Wonder if we see fireworks in the next couple weeks (either way) with something coming out after the meeting.

1 · Reply

cesar5550 Jan. 27 at 2:51 PM

$KALA

0 · Reply

EZGREENMONEY Jan. 26 at 5:22 PM

$KALA Watch out! It will get crazy soon!

0 · Reply

Banelamhh Jan. 26 at 3:58 PM

$KALA bs

0 · Reply

LoganzzRunn Jan. 24 at 7:53 AM

$KALA Good news 👍 KALA BIO, Inc. (Form: 8-K, Received: 01/23/2026 16:05:58) https://share.google/mmgRIIS1N7eVsBxNL

2 · Reply

AlwaysHydrated Jan. 23 at 8:20 PM

$KALA

1 · Reply

LoganzzRunn Jan. 23 at 4:57 PM

$KALA low volume selloff the last few days. Combine no news with some probable dilution by the lenders that were paid off and it is back under .60.

0 · Reply

Jjjjen Jan. 23 at 3:13 PM

$KALA when will we see a dollar.here

0 · Reply

KALA BIO Settles Approximately $10.6 million of Debt

Dec 4, 2025, 10:45 AM EST - 7 weeks ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 29, 2025, 12:00 PM EDT - 4 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Aug 8, 2025, 8:00 AM EDT - 6 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 6 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 7 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 8 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 19, 2023, 7:12 AM EST - 3 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 4 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 10:54 AM EDT - 4 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:00 AM EDT - 4 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 2, 2022, 1:25 PM EDT - 4 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 1, 2022, 9:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

OfficialStocktwitsUser Jan. 28 at 2:52 AM

0 · Reply

ALOSETE Jan. 27 at 9:38 PM

$KALA Nice close. In lazar we trust.🤑

0 · Reply

EF5Stocks Jan. 27 at 6:56 PM

1 · Reply

cesar5550 Jan. 27 at 2:51 PM

$KALA

0 · Reply

EZGREENMONEY Jan. 26 at 5:22 PM

$KALA Watch out! It will get crazy soon!

0 · Reply

Banelamhh Jan. 26 at 3:58 PM

$KALA bs

0 · Reply

LoganzzRunn Jan. 24 at 7:53 AM

$KALA Good news 👍 KALA BIO, Inc. (Form: 8-K, Received: 01/23/2026 16:05:58) https://share.google/mmgRIIS1N7eVsBxNL

2 · Reply

AlwaysHydrated Jan. 23 at 8:20 PM

$KALA

1 · Reply

LoganzzRunn Jan. 23 at 4:57 PM

$KALA low volume selloff the last few days. Combine no news with some probable dilution by the lenders that were paid off and it is back under .60.

0 · Reply

Jjjjen Jan. 23 at 3:13 PM

$KALA when will we see a dollar.here

0 · Reply

TheBullishOne007 Jan. 23 at 3:41 AM

$KALA Getting closer to boom boom time here. 🤙

1 · Reply

VOO_And_Chill Jan. 22 at 2:51 PM

$KALA $SOWG seems my call was at least half accurate for now

0 · Reply

AlwaysHydrated Jan. 22 at 2:36 PM

$KALA Pinned to .60, not a bad thing love me a long accumulation phase. Hopefully big boom follows.

0 · Reply

BonChonzo Jan. 21 at 1:43 PM

$KALA going down as expected. 0.50 next

1 · Reply

Stock_Catcher Jan. 21 at 3:01 AM

Wealthy Wednesday Watchlist Pt.5 $IOVA $ALT $GALT $CGTL $KALA Let's Do Great Tomorrow 📈

0 · Reply

VOO_And_Chill Jan. 20 at 9:15 PM

Unpopular opinion - I think $KALA will hold $1 before $SOWG, even despite the recent test of $1+ since $KALA I believe will have more substantial news to support a higher evaluation in a shorter period of time. Where as $SOWG I believe is further behind with such developments. All IMO of course and long on both for the speculation.

1 · Reply

BonChonzo Jan. 19 at 3:49 PM

$KALA I hope no ATM

1 · Reply

rombrento Jan. 18 at 8:35 PM

$KALA

0 · Reply

EF5Stocks Jan. 18 at 5:10 PM

$KALA Interesting setup here for sure. Lazar has a proven track record of "rescuing" shareholder value for distressed companies like $KALA. Additionally, the chart has that massive open gap from $20. Now, of course, that is due to the trial failure so one should not expect it to entirely fill but that coupled with the potential "W" pattern showing up on the broader chart makes for an interesting setup. Hopefully through his connections, Lazar can make something big happen here for us and restore value to $KALA.

0 · Reply

VOO_And_Chill Jan. 18 at 11:33 AM

Unpopular opinion - I think $KALA and hold $1 before $SOWG even despite the recent test of $1+ since $KALA I believe we’ll have more substantial news to support a higher evaluation in a shorter period of time, where as $SOWG I believe is further behind with such developments. All INO of course and long on both for the speculation.

0 · Reply

Bigdubs Jan. 16 at 7:16 PM

$KALA nice move up! Glad I was able to top off at .601 yesterday AH. Remember patience here, don’t expect any news before the meeting but if it comes, great (assuming good news)!

0 · Reply

JoaoCarvalho Jan. 16 at 7:13 PM

$KALA 0.72 ar the end

0 · Reply

Market Cap	5.72M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-3.28

Volume	620,000
Avg Vol	9,830,226
Day's Range	N/A - N/A
Shares Out	9.83M
Stochastic %K	21%
Beta	-2.43
Analysts	Hold
Price Target	$1.50